124I-evuzamitide Clinical Trials (2026): 4 Studies for Cardiac Amyloidosis & Amyloidogenic Transthyretin (ATTR) Amyloidosis
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
4 124I-evuzamitide clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 4 indications (including Cardiac Amyloidosis & Amyloidogenic Transthyretin (ATTR) Amyloidosis) and 279 total planned enrollment. 1 Phase 3 124I-evuzamitide trial and 2 Phase 2 are listed. 2 124I-evuzamitide clinical trials are actively recruiting. Most recent activity: NCT07538518 (Apr 2028).
124I-evuzamitide clinical trials at a glance: phase × recruitment status
| Phase | enrolling by invitation | completed | not yet recruiting | Total |
|---|---|---|---|---|
| P2 | 1 | 1 | 2 | |
| P3 | 1 | 1 | ||
| N/A | 1 | 1 |
Recruiting 124I-evuzamitide clinical trials (2)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT07538518 | TRACEPET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels | — | Amyloidogenic Transthyretin (ATTR) Amyloidosis | 25 | Jun 2026 |
| NCT06907849 | 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome | P2 | Lumbar Spinal Stenosis | 40 | May 2025 |
124I-evuzamitide clinical trials by indication
Amyloidogenic Transthyretin (ATTR) Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07538518 | TRACE | N/A | not yet recruiting | PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels |
Lumbar Spinal Stenosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06907849 | — | P2 | enrolling by invitation | 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome |
Cardiac Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06788535 | REVEAL | P3 | completed | REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis |
Transthyretin Amyloidosis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05635045 | — | P2 | completed | Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR |
124I-evuzamitide pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| REVEAL | NCT06788535 | P3 | completed | Cardiac Amyloidosis | 204 | PMID 37940323 |
All 124I-evuzamitide trials (4)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT07538518 | TRACE | PET Imaging Study Using Evuzamitide to Detect Cardiac Amyloidosis in Patients With Inconclusive Nuclear Scans and Elevated TAD1 Levels | — | not yet recruiting | 25 | Lorena Saelices | Jun 2026 |
| NCT06907849 | 124I-Evuzamitide PET/CT Imaging In Patients With Lumbar Spinal Stenosis and Carpal Tunnel Syndrome | P2 | enrolling by invitation | 40 | University of Tennessee Graduate School of Medicine | May 2025 | |
| NCT06788535 | REVEAL | REVEAL - Research With I-124 EVuzamitide to Elucidate Cardiac AmyLoidosis | P3 | completed | 204 | Sharmila Dorbala | Jan 2025 |
| NCT05635045 | Evuzamitide in PET/CT to Measure Potential Therapeutic Response in ATTR | P2 | completed | 10 | Columbia University | Jul 2022 |
124I-evuzamitide clinical trials: frequently asked questions
- How many 124I-evuzamitide clinical trials are there?
- 4 124I-evuzamitide clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 1 is actively recruiting participants. 2 are marked completed.
- Are 124I-evuzamitide clinical trials recruiting in 2026?
- Yes — 1 124I-evuzamitide trial is actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is 124I-evuzamitide being studied for?
- 124I-evuzamitide is being studied for Cardiac Amyloidosis, Amyloidogenic Transthyretin (ATTR) Amyloidosis, Carpal Tunnel Syndrome (CTS), Lumbar Spinal Stenosis, Transthyretin Amyloidosis. The trials are grouped by indication on this page.
- What phase is 124I-evuzamitide in?
- 124I-evuzamitide clinical trials span 1 Phase 3, 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors 124I-evuzamitide clinical trials?
- The lead sponsor across the most 124I-evuzamitide trials is Columbia University, with 3 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming 124I-evuzamitideas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: